REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Oxygen Containing Hetero Ring > The Hetero Ring Is Five-membered > Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos > Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos Bicyclo Ring System Having The Hetero Ring As One Of The CyclosBicyclo Ring System Having The Hetero Ring As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027209 - Prevention and treatment of atherosclerosis with lithospermate b This invention relates to lithospermate B (‘LAB’ hereinafter) that inhibits proliferation and migration of vascular smooth muscle cells (‘VSMC’ hereinafter). More specifically, this invention relates to a pharmaceutical composition comprising LAB isolated from Salviae miltiorrhiza as an active ingredient for treating atherosclerosis. ... 01/25/07 - 20070021499 - Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a ... 01/11/07 - 20070010576 - Bycyclic tetrahydrofuran derivatives and process for the preparation thereof wherein n is 1 or 2; R is phenyl optionally substituted with C1-C6 alkyl, C1-C6 alkoxy, hydroxyl or C1-C6 hydroxyalkyl group; and R1 is C1-C6 alkyl group. ... 12/07/06 - 20060276535 - Novel compounds for treatment of cardiac arrhythmia and methods of use The subject invention provides novel compounds for treatment of cardiac arrhythmia and methods of use. ... 11/16/06 - 20060258739 - Dihydrobenzofuran derivatives and uses therof or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, y, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. Such compounds, and compositions thereof, are useful for treating a ... 11/09/06 - 20060252825 - Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride The present invention is directed to crystalline forms of the 5-HT2C agonist {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride, as well as compositions, processes of preparation, and uses thereof. ... 10/26/06 - 20060241176 - Dihydrobenzofuran derivatives and uses thereof or pharmaceutically acceptable salts thereof, wherein each of R1, R2, R3, R4, Rx, Ry, and n are as defined herein. Such compounds, and compositions thereof, are useful for treating a variety of central nervous system disorders such as schizophrenia. ... 08/24/06 - 20060189683 - Parenteral formulation of mycophenolic acid, a salt or prodrug thereof A pharmaceutical composition in the form of powder or a lyophilized composition for injection suitable for parenteral administration comprising MPA, a salt or a produg thereof. ... 07/27/06 - 20060167085 - Active substance combinations having insecticidal and acaricidal properties The invention relates to novel active compound combinations of certain cyclic ketoenols and certain active compounds that together have unexpectedly good insecticidal and acaricidal properties. ... 06/08/06 - 20060122265 - Process for modifying drug crystal formation A process for modifying the crystal habit of acicular drug substances, crystals obtained by such a process, and particular crystal forms or modifications of mycophenolic acid or mycophenolate sodium are provided, as well as pharmaceutical compositions comprising the crystals, methods of treatment and uses thereof. ... 05/25/06 - 20060111438 - Asymmetric synthesis of substituted dihydrobenzofurans where Ar, Y, R1, Ry, R2, and m are as defined herein. ... 05/18/06 - 20060106097 - Metabolism-modulating agents and uses therefor The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5′ monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to ... 05/18/06 - 20060106096 - Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists The invention relates to novel benzothiophene-, benzofuran- and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. ... 05/11/06 - 20060100270 - Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof The invention relates to a method for preventing, attenuating or treating pulmonary hypertension in an individual in need thereof, comprising administering at least one 5-HTT inhibitor to said individual. ... 05/04/06 - 20060094776 - Insecticidal (dihalopropenyl) phenylalkyl substituted dihydrobenzofuran and dihydrobenzopyran derivatives where the asterisk denotes attachment at A; and q, r, s, u, v and w are integers independently selected from 0, 1 and 2; and t is an integer selected from 0 and 1. A, D, E, G, M, R through R11, and R16 through R27, inclusively, are fully described ... 04/27/06 - 20060089405 - Asymmetric synthesis of dihydrobenzofuran derivatives wherein each of R1, R2, R3, and R4 is as defined herein. ... 04/06/06 - 20060074128 - Substituted 2-phenyl benzofurans as estrogenic agents wherein R, R′, A, A′, X, Y, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof. ... 03/30/06 - 20060069152 - Crystalline mycophenolate sodium Provided are crystalline mycophenolate sodium forms and processes for their preparation. ... 03/23/06 - 20060063830 - Method for treating gastrointestinal disorder The present invention relates to a method for the long term treatment of gastrointestinal disorders in a human subject, which comprises administering an effective amount of a halogenated prostaglandin compound and/or its tautomer to the subject. The method induces substantially no electrolyte shifting during the term of the treatment. The ... 03/16/06 - 20060058377 - Novel compounds and methods for inhibiting cellular responses to hypoxia and analogs and stereoisomers thereof (and pharmaceutically acceptable carriers). Additionally disclosed is a method of inhibiting hypoxia-inducible factor-1 function in a patient or sample thereof, comprising administering to the patient or sample an effective inhibiting amount of a compound or composition of the present invention. ... 01/19/06 - 20060014827 - 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia wherein (a) is a single or double bond; W is CH, CH2, CHCH3, CCH3, C(CH3)2, C(CH2)2 or C(CH2)3, provided that when (a) is a double bond, then W is CH or CCH3, and when (a) is a single bond, then W is CH2, CHCH3, C(CH3)2, C(CH2)2 or C(CH2)3; X is ... 01/12/06 - 20060009515 - Process and intermediates for preparing escitalopram The antidepressant drug Escitalopram is prepared from 5-bromophthalide via the diol intermediate (4-bromo-2-(hydrox-ymethyl)phenyl)-(4-fluorophenyl)methanol. The racemic diol intermediate is converted to an enantiomerically enriched form by first converting the diol to a monoester intermediate and then reacting the monoester intermediate with an optically active acid, most preferably (+)-di-p-toluoyl tartaric acid, to ... 10/13/05 - 20050228045 - Novel compounds for treatment of cardiac arrhythmia and methods of use The subject invention provides novel compounds for treatment of cardiac arrhythmia and methods of use. ... 10/13/05 - 20050228044 - Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders A class of benzodihydrofuran compounds having the structure of formula (I) below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are ... 09/29/05 - 20050215627 - Application of substances acting as cascade inhibitors of the raf/mek/erk signaling cascade for the production of a drug against dna and rna viruses The invention consists in that substances acting as cascade inhibitors of the Raf/MEK/ERK signaling pathway, in particular MEK inhibitors, are used for the production of a drug for the preventive and antiviral therapy against DNA and RNA viruses, in particular against intranuclear-replicating negative strand RNA viruses, for instance influenza or ... 09/29/05 - 20050215626 - Substituted benzofuran oximes The present invention relates to substituted benzofuran oximes and methods of using them. ... 09/22/05 - 20050209316 - Lactone formulations and method of use wherein R1-R9 and Y1-Y3 taken independently are preferably a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic groups or groupings which optionally include a heteroatom such as oxygen, sulfur, or nitrogen groupings in linear, branched, or cyclic structural formats; Z and X are independently and preferably ... 09/08/05 - 20050197388 - Crystalline composition containing escitalopram The present invention discloses crystalline particles of escitalopram oxalate which either have a broad particle size distribution or comprise at least 0.01% (w/w) of Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile, said particles being suitable for use in direct compression. Furthermore, the invention discloses a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram ... 09/01/05 - 20050192344 - Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites Methods for prophylaxis of or treating or preventing migraine or migraine headaches, or other headache disorders include administering to a subject in need of treatment a therapeutically effective amount of citalopram, escitalopram, or a racemic or optically pure citalopram metabolite, or pharmaceutically acceptable salts, solvates, polymorphs, or hydrates thereof. ... 08/11/05 - 20050176813 - Novel chalcone derivatives and uses thereof Various chalcone derivatives of the general formula (I) are described and the variables, A, B, m and R1 to R10 are as defined in the specification. These derivatives can be useful in the modulation of potassium channel activity in cells and may be useful in the treatment or prevention of ... 07/28/05 - 20050165092 - Crystalline base of citalopram The present invention relates to the crystalline base of the well known antidepressant drug citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of citalopram, such as the hydrobromide, using the base, the salts obtained by said process and formulations containing such salts. ... 07/21/05 - 20050159481 - Medicinal composition for improving angiotension-regulating function of blood vessel endothelium R1 represents a hydrogen atom or an acyl or arylalkyloxycarbonyl group; R2 and R3 are identical or different and represent an optionally substituted alkyl group, an optionally substituted alkenyl group or an optionally substituted alkynyl group; or R2 and R3 may together form a cycloalkyl group. ... 07/14/05 - 20050154053 - Methods and compositions for immunomodulation Novel antigens are provided herein. The antigens are associated with recognition of CD1 molecules by T cells. These antigens can be used as antigens, adjuvants or as immunomodulatory agents in a variety of therapeutic and prophylactic applications. ... 07/14/05 - 20050154052 - Novel crystalline forms of (s)-citalopram oxalate The present invention relates to novel crystalline forms of (S)-citalopram oxalate, to processes for their preparation and to pharmaceutical compositions containing them. ... 07/14/05 - 20050154051 - Method for the preparation of escitalopram The invention relates to a method for the preparation of escitalopram by cyanation of optically active intermediates of the formulas (III) and (II) below, and the preparation of such intermediates by optical resolution. ... 06/30/05 - 20050143452 - Dihydrobenzofuranyl alkanamine derivatives and methods for using same which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia. ... 06/23/05 - 20050137255 - Crystalline escitalopram hydrobromide and methods for preparing the same The present invention provides crystalline escitalopram hydrobromide ((S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furan carbonitrile hydrobromide), and a novel crystalline form of escitalopram hydrobromide referred to herein as Form I. Form I is stable, water soluble, and not hygroscopic at a relative humidity less than 70%. ... 06/23/05 - 20050137254 - 2-phenylbenzofuran derivatives, a process for preparing them, and their use which are formed, during fermentation, by the microorganism Aspergillus flavipes ST003878 (DSM 15290), to a process for preparing them and to their use as pharmaceuticals for the treatment and/or prophylaxis of bacterial infectious diseases or mycoses. ... 06/02/05 - 20050119338 - Combination of cytochome p450 dependent protease inhibitors The present invention relates to a method for improving the pharmacokinetics of hexahydrofuro[2,3-b]furanyl containing HIV protease inhibitors comprising administering to a human in need thereof a combination of a therapeutically effective amount of a hexahydrofuro[2,3-b]furanyl containing HIV protease inhibitor, and a therapeutically effective amount of a cytochrome P450 inhibitor. ... ### FreshPatents.com Support |